The most commonly noted all grade adverse events in patients receiving post‐CRT durvalumab consolidation included skin rash (seven patients; 24.1%), pruritus (five patients; 17.2%), pneumonitis (five patients; 17.2%), elevated AST/ALT (three patients; 10.3%), diarrhea (three patients; 10.3%) and cough (three patients; 10.3%; Table 4). This evidence concerns the gene GPT and pneumonitis.